09:53 AM EDT, 09/17/2025 (MT Newswires) -- Palisade Bio ( PALI ) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.

The study also showed "promising" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.

PALI-2108 also showed a "favorable" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.

The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.

Palisade shares were up more than 4% in recent trading Wednesday.

Price: 0.63, Change: +0.03, Percent Change: +4.58